Cargando…
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
Poly-ADP-ribosyltransferases play a critical role in DNA repair and cell death, and poly(ADP-ribosyl) polymerase 1 (PARP1) is a particularly important therapeutic target for the treatment of breast cancer because of its synthetic lethal relationship with breast cancer susceptibility proteins 1 and 2...
Autores principales: | Ryan, Kevin, Bolaňos, Ben, Smith, Marissa, Palde, Prakash B., Cuenca, Paulina Delgado, VanArsdale, Todd L., Niessen, Sherry, Zhang, Lianglin, Behenna, Douglas, Ornelas, Martha A., Tran, Khanh T., Kaiser, Stephen, Lum, Lawrence, Stewart, Al, Gajiwala, Ketan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Biochemistry and Molecular Biology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7948648/ https://www.ncbi.nlm.nih.gov/pubmed/33361107 http://dx.doi.org/10.1074/jbc.RA120.016573 |
Ejemplares similares
-
A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
por: Xue, Huijun, et al.
Publicado: (2022) -
PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
por: Ding, Xia, et al.
Publicado: (2022) -
The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006) -
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2
por: Qiu, Wei, et al.
Publicado: (2014) -
Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development
por: Chiang, Y. Jeffrey, et al.
Publicado: (2008)